Marksans Pharma Dividends and Buybacks
Dividend criteria checks 3/6
Marksans Pharma is a dividend paying company with a current yield of 0.2% that is well covered by earnings.
Key information
0.2%
Dividend yield
0.05%
Buyback Yield
| Total Shareholder Yield | 0.3% |
| Future Dividend Yield | 1.1% |
| Dividend Growth | 4.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹0.600 |
| Payout ratio | 9% |
Recent dividend and buyback updates
Recent updates
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Nov 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: MARKSANS's dividend payments have been volatile in the past 10 years.
Growing Dividend: MARKSANS's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Marksans Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MARKSANS) | 0.2% |
| Market Bottom 25% (IN) | 0.2% |
| Market Top 25% (IN) | 1.1% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (MARKSANS) (up to 3 years) | 1.1% |
Notable Dividend: MARKSANS's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.24%).
High Dividend: MARKSANS's dividend (0.2%) is low compared to the top 25% of dividend payers in the Indian market (1.13%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (8.7%), MARKSANS's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (52.3%), MARKSANS's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 12:32 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marksans Pharma Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |